81_FR_31347 81 FR 31251 - National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

81 FR 31251 - National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 96 (May 18, 2016)

Page Range31251-31251
FR Document2016-11663

Federal Register, Volume 81 Issue 96 (Wednesday, May 18, 2016) 
[Federal Register Volume 81, Number 96 (Wednesday, May 18, 2016)]
[Notices]
[Page 31251]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-11663]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Dental & Craniofacial Research; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Dental and Craniofacial 
Research Special Emphasis Panel; NIDCR Data Analysis and Statistical 
Methodology PARs.
    Date: June 10, 2016.
    Time: 11:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, One Democracy Plaza, 6701 
Democracy Boulevard, Bethesda, MD 20892.
    Contact Person: Victor Henriquez, Ph.D., Scientific Review 
Officer DEA/SRB/NIDCR, 6701 Democracy Blvd., Room 668, Bethesda, MD 
20892-4878, 301-451-2405, henriquv@nidcr.nih.gov.

    Name of Committee: NIDCR Special Grants Review Committee.
    Date: June 16-17, 2016.
    Time: 8:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Wyndham San Antonio Riverwalk 111 East Pecan Street, San 
Antonio, TX 78205
    Contact Person: Marilyn Moore-Hoon, Ph.D., Scientific Review 
Officer, Scientific Review Branch, National Institute of Dental and 
Craniofacial Research, 6701 Democracy Blvd., Rm. 676, Bethesda, MD 
20892-4878, 301-594-4861, mooremar@nidcr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral 
Diseases and Disorders Research, National Institutes of Health, HHS)

    Dated: May 12, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-11663 Filed 5-17-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 96 / Wednesday, May 18, 2016 / Notices 31251 Dated: May 12, 2016. Dated: May 12, 2016. exclusively licensed to the Government Richard U. Rodriguez, Natasha M. Copeland, of the United States of America. Associate Director, Technology Transfer Program Analyst, Office of Federal Advisory The prospective exclusive licensed Center, National Cancer Institute. Committee Policy. territory may be the United States, [FR Doc. 2016–11661 Filed 5–17–16; 8:45 am] [FR Doc. 2016–11663 Filed 5–17–16; 8:45 am] Australia, Canada, the European Union, BILLING CODE 4140–01–P Russia, China, Hong Kong, Japan, BILLING CODE 4140–01–P Taiwan, South Korea and Singapore, and the field of use may be limited to: DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND ‘‘The development of a glypican-3 HUMAN SERVICES HUMAN SERVICES (GPC3) chimeric antigen receptor (CAR)- based immunotherapy using autologous National Institutes of Health National Institutes of Health (meaning one individual is both the donor and the recipient) primary human National Institute of Dental & Prospective Grant of an Exclusive lymphocytes (T cells or NK cells) License: The Development of an Anti- transfected with a lentiviral or retroviral Craniofacial Research; Notice of GPC3 Chimeric Antigen Receptor vector, wherein the vector expresses a Closed Meetings (CAR) Based on YP7 for the Treatment CAR having (1) a single antigen Pursuant to section 10(d) of the of Human Cancers specificity and (2) comprising at least: Federal Advisory Committee Act, as AGENCY: Public Health Service, National (a) The complementary determining amended (5 U.S.C. App.), notice is Institutes of Health, HHS. region (CDR) sequences of the anti-GPC3 hereby given of the following meetings. ACTION: Notice. antibody known as YP7; and (b) a T cell signaling domain; for the prophylaxis The meetings will be closed to the SUMMARY: This notice, in accordance and treatment of GPC3-expressing public in accordance with the with 35 U.S.C. 209(c)(1) and 37 CFR cancers.’’ provisions set forth in sections Part 404.7(a)(1)(i), that the National DATES: Only written comments and/or 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Institutes of Health, Department of applications for a license which are as amended. The grant applications and Health and Human Services, is received by the NCI Technology the discussions could disclose contemplating the grant of an exclusive Transfer Center on or before June 2, confidential trade secrets or commercial license to practice the inventions 2016 will be considered. property such as patentable material, embodied in: and personal information concerning ADDRESSEES: Requests for copies of the individuals associated with the grant Intellectual Property patent application, inquiries, comments, applications, the disclosure of which U.S. Provisional Patent Application and other materials relating to the would constitute a clearly unwarranted 61/654,232 entitled ‘‘High-affinity contemplated exclusive license should invasion of personal privacy. Monoclonal Antibodies To Glypican-3 be directed to: David A. Lambertson, Name of Committee: National Institute of And Use Thereof’’ [HHS Ref. E–136– Ph.D., Senior Licensing and Patenting Dental and Craniofacial Research Special 2012/0–US–01]; PCT Patent Application Manager, National Cancer Institute, Emphasis Panel; NIDCR Data Analysis and PCT/US2013/043633 entitled ‘‘High- 9609 Medical Center Drive, Rm 1–E530 Statistical Methodology PARs. affinity Monoclonal Antibodies To MSC9702, Rockville, MD 20850–9702, Date: June 10, 2016. Glypican-3 And Use Thereof’’ [HHS Ref. Email: david.lambertson@nih.gov. Time: 11:00 a.m. to 4:00 p.m. E–136–2012/0–PCT–02]; Chinese Patent SUPPLEMENTARY INFORMATION: This Agenda: To review and evaluate grant Application 201380039993.7 entitled invention concerns an anti-GPC3 applications. ‘‘High-affinity Monoclonal Antibodies (Glypican-3) chimeric antigen receptor Place: National Institutes of Health, One To Glypican-3 And Use Thereof’’ [HHS (CAR) and methods of using the CAR for Democracy Plaza, 6701 Democracy Ref. E–136–2012/0–CN–03]; Japanese the treatment of GPC3-expressing Boulevard, Bethesda, MD 20892. Patent Application 2015–515243 cancers. GPC3 is a cell surface antigen Contact Person: Victor Henriquez, Ph.D., entitled ‘‘High-affinity Monoclonal that is preferentially expressed on Scientific Review Officer DEA/SRB/NIDCR, Antibodies To Glypican-3 And Use certain types of cancer cells, particularly 6701 Democracy Blvd., Room 668, Bethesda, liver cancers such as hepatocellular Thereof’’ [HHS Ref. E–136–2012/0–JP– MD 20892–4878, 301–451–2405, henriquv@ carcinoma (HCC). The anti-GPC3 CARs 04]; South Korea Patent Application 10– nidcr.nih.gov. 2014–7037046 entitled ‘‘High-affinity of this technology contain (1) antigen Name of Committee: NIDCR Special Grants Monoclonal Antibodies To Glypican-3 recognition sequences that bind Review Committee. And Use Thereof’’ [HHS Ref. E–136– specifically to GPC3 and (2) signaling Date: June 16–17, 2016. domains that can activate the cytotoxic 2012/0–KR–05]; Singapore Patent Time: 8:00 a.m. to 12:00 p.m. Application 11201407972R entitled functions of a T cell. The anti-GPC3 Agenda: To review and evaluate grant ‘‘High-affinity Monoclonal Antibodies CAR can be transduced into T cells that applications. Place: Wyndham San Antonio Riverwalk To Glypican-3 And Use Thereof’’ [HHS are harvested from a donor, followed by 111 East Pecan Street, San Antonio, TX Ref. E–136–2012/0–SG–06]; United (a) selection and expansion of the T 78205 States Patent Application 14/403,896 cells expressing the anti-GPC3 CAR, and Contact Person: Marilyn Moore-Hoon, entitled ‘‘High-affinity Monoclonal (b) reintroduction of the T cells into the Ph.D., Scientific Review Officer, Scientific Antibodies To Glypican-3 And Use patient. Once the anti-GPC3 CAR- Thereof’’ [HHS Ref. E–136–2012/0–US– expressing T cells are reintroduced into sradovich on DSK3TPTVN1PROD with NOTICES Review Branch, National Institute of Dental and Craniofacial Research, 6701 Democracy 07]; the patient, the T cells can selectively Blvd., Rm. 676, Bethesda, MD 20892–4878, and all continuing U.S. and foreign bind to GPC3-expressing cancer cells 301–594–4861, mooremar@nidcr.nih.gov. patents/patent applications for the through its antigen recognition (Catalogue of Federal Domestic Assistance technology family, to Lentigen sequences, thereby activating the T cell Program Nos. 93.121, Oral Diseases and Technology, Inc. through its signaling domains to Disorders Research, National Institutes of The patent rights to these inventions selectively kill the cancer cells. Through Health, HHS) have been assigned to and/or this mechanism of action, the selectivity VerDate Sep<11>2014 17:10 May 17, 2016 Jkt 238001 PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\18MYN1.SGM 18MYN1


Document Created: 2016-05-18 00:06:11
Document Modified: 2016-05-18 00:06:11
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesJune 10, 2016.
FR Citation81 FR 31251 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR